Press Releases

SOUTH SAN FRANCISCO, Calif., July 9, 2019 /PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced that Lori Friedman, PhD, has been named Chief Scientific Officer. Dr. Friedman will serve on the executive lea

SAN FRANCISCO, July 9, 2019 /PRNewswire/ -- Genstar Capital, a leading private equity firm focused on investments in targeted segments of the financial services, healthcare, industrial technology and software industries, announced today that it has completed the previously announced acquisition of Advarra (the "Company"), a leading provider of compliance solut

PRINCETON, N.J., July 9, 2019 /PRNewswire/ -- Sandoz Inc. (Sandoz), a Novartis division, today announced the US retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the nation.

Consulting Hypnotists Help Ordinary People with Ordinary Problems MERRIMACK, N.H., July 9, 2019 /PRNewswire/ -- The National Guild of Hypnotists will convene their 32nd Annual Convention and Educational Conference on August 9th -11th in

DUBLIN, July 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that the company will present 29 abstracts at the 61st American Headache Society (AHS) Meeting, including one late-breaking podium presentation, five oral podium presentations and 23 poster presentations. The presentations will continue to highlight Allergan's ongoing innovation in

Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease TORONTO and CAMBRIDGE, MA, July 9, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focu

CAMBRIDGE, Mass., July 9, 2019 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine company, today announced a $23 million Series D fundraising round, led by Cigna Ventures, a strategic corporate venture capital partner and wholly owned indirect subsidiary of Cigna Corporation (NYSE: CI). Joining the Cign

LOS ANGELES, July 9, 2019 /PRNewswire/ -- Zynx Health™, market leader in providing evidence- and experience-based clinical improvement solutions since 1996, announced today that long-time client

REDWOOD CITY, Calif., July 9, 2019 /PRNewswire/ -- REVOLUTION Medicines, Inc., a clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, today announced the closing of a $100 million Series C equity financing.  Proceeds will support continued

TORONTO and HOUSTON, July 9, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$1,915,264 (approximately, CD$2.5M) from the Cancer Prevention and Research Institute of